Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Cloud Pharmaceuticals looks to the crowd
December 2016
SHARING OPTIONS:

RESEARCH TRIANGLE PARK, N.C.—Cloud Pharmaceuticals Inc. is going to the people with a crowdfunding effort to finance orphan drug discovery for amyotrophic lateral sclerosis (ALS, or Lou Gehrig's disease) and Zika virus. The company hopes to fast-track its efforts with its rapid discovery platform, which combines artificial intelligence, cloud computing and molecular modeling to design novel drugs. Should its drug design efforts prove successful, Cloud Pharmaceuticals intends to continue compound design and develop the compounds itself or with partners.
 
“ALS and Zika virus have devastating effects on those afflicted. But research is limited because of each disease’s orphan status,” commented Cloud Pharmaceuticals CEO Ed Addison. “The diseases affect a relatively small percentage of the population, so there is less incentive for pharmaceutical companies to invest in efforts to treat or prevent the diseases. Crowdfunding enables us to fund that work and continue our efforts to improve health and well-being through the computational design and rapid development of new therapies.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.